必贝特

688759 SSE 证监会行业分类 C27医药制造业

Key Metrics

Market Cap

17.1B ($2.5B)

P/E Ratio

N/A

P/B Ratio

N/A

Revenue

N/A

Net Income

-56.0M

Gross Margin

N/A

Op. Margin

N/A

Net Margin

N/A

ROE

-19.3%

ROA

-16.9%

D/E

0.15

Dividend Yield

N/A

EPS

-0.16

Current Ratio

6.07

Price History

Company Info

Industry	C27医药制造业
Market Segment	STAR Market
Currency	CNY
Fiscal Year	2024

Business Overview

BeBetter Med Inc., a biopharmaceutical company, engages in the research and development, and sale of drugs for tumors, autoimmune diseases, and metabolic diseases. It is developing BEBT-908, a PI3K/HDAC dual-target small molecule inhibitor for antitumor; BEBT-209, a CDK4 highly selective CDK4/6 inhibitor for antitumor; BEBT-109, a pan-mutant EGFR inhibitor for antitumor; BEBT-260, a ChK1 inhibitor for antitumor; BEBT-305, a second-generation HSP90 inhibitor for autoimmune disease; BEBT-503, a pan-PPAR agonist for metabolic disease; BEBT-607, a KRAS G12C inhibitor for antitumor; BEBT-808, an or...

Full Financials Advanced Charts Filings

Peers

工商银行

601398

2.7T

P/E: 7.6

建设银行

601939

2.5T

P/E: 7.2

农业银行

601288

2.4T

P/E: 8.7

中国海油

600938

2.0T

P/E: 16.2

宁德时代

300750

1.9T

P/E: 25.6

贵州茅台

600519

1.8T

P/E: 20.1

中国银行

601988

1.8T

P/E: 7.3

中国人寿

601628

1.2T

P/E: 6.9

Financial Statements

Loading financials...

Open Advanced Charts

Full charting with technical indicators, candlestick, and more.

About 必贝特

Ticker	688759
Exchange	SSE
Sector	证监会行业分类
Industry	C27医药制造业